Who are PecFent and Epistatus's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pecfent-and-epistatus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PecFent and Epistatus — Competitive Intelligence Brief

PecFent and Epistatus (PecFent and Epistatus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic (PecFent); Benzodiazepine anticonvulsant (Epistatus). Area: Pain management (PecFent); Neurology/Seizure disorders (Epistatus).

marketed Opioid analgesic (PecFent); Benzodiazepine anticonvulsant (Epistatus) Mu-opioid receptor (PecFent); GABA-A receptor (Epistatus) Pain management (PecFent); Neurology/Seizure disorders (Epistatus) Small molecule Live · refreshed every 30 min

Target snapshot

PecFent and Epistatus (PecFent and Epistatus) — Gloucestershire Hospitals NHS Foundation Trust. PecFent is a fentanyl nasal spray that delivers rapid opioid analgesia through intranasal absorption, while Epistatus is a midazolam buccal liquid that provides rapid seizure termination through GABA-A receptor agonism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PecFent and Epistatus TARGET	PecFent and Epistatus	Gloucestershire Hospitals NHS Foundation Trust	marketed	Opioid analgesic (PecFent); Benzodiazepine anticonvulsant (Epistatus)	Mu-opioid receptor (PecFent); GABA-A receptor (Epistatus)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic (PecFent); Benzodiazepine anticonvulsant (Epistatus) class)

Gloucestershire Hospitals NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PecFent and Epistatus — Competitive Intelligence Brief. https://druglandscape.com/ci/pecfent-and-epistatus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab